Table 2.

Patient-based characteristics

Pat	Age	T1	T2	GSC	ADT	ADT (days)	CTx	Initial PSA (ng/ml)	PSA after ADT		∑ PSMA-TV at T2 in % of T1	∑ TL-PSMA at T2 in % of T1
									(ng/ml)	[% of T1]
1	60	MR	CT2	4 + 3	B	219	6 Cycles	80	0.41	0.5	4.50	5.89
2	64	CT1	CT2	5 + 4	L	289	6 Cycles	5.9	0.15	2.5	2.80	4.34
3	59	CT1	CT1	5 + 4	Max	279	6 Cycles	2.49	0.27	10.8	12.62	8.95
4	74	CT1	CT2	4 + 4	Max	149	X	29.14	0.69	2.4	9.65	15.78
5	57	MR	CT2	4 + 3	Max	218	X	45.4	0.71	1.6	38.12	94.63
6	74	MR	MR	4 + 4	Max	61	X	57.5	1.42	2.5	35.12	28.80
7	73	MR	MR	4 + 5	Max	98	X	14.06	0.1	0.7	16.71	11.42
8	74	CT1	MR	4 + 3	Max	115	X	25.8	0.05a	0.2	23.35	2.94
9	79	MR	CT1	4 + 5	Max	156	X	42.06	1.9	4.5	44.38	33.59
10	79	MR	CT1	4 + 4	B	116	X	17.97	1.52	8.5	53.13	50.02
11	76	CT1	CT1	4 + 3	Max	118	X	100.4	1.93	1.9	39.57	9.29
12	65	MR	CT1	4 + 5	Max	155	X	91.5	0.09	0.1	0.00	0.00
13	59	CT1	CT1	4 + 4	Max	81	X	32.9	3.08	9.4	206.69	267.85
14	66	CT1	CT1	4 + 4	Max	168	6 Cycles	107	0.21	0.2	42.53	6.50
15	74	CT1	CT1	4 + 4	Max	174	X	16.17	0.93	5.8	16.96	2.73
16	80	CT1	CT1	4 + 5	Max	253	X	12.07	0.45	3.7	63.50	30.34
17	66	CT1	CT1	3 + 4	Max	205	4 Cycles	31.5	0.05	0.2	0.00	0.00
18	70	CT1	CT1	4 + 4	Max	109	X	21	4.91	23.4	59.97	51.12
19	81	CT2	CT2	4 + 3	Max	102	X	26.13	3.53	13.5	45.78	40.14
20	57	CT2	MR	5 + 4	Max	134	X	36.2	1.34	3.7	52.09	6.18
21	59	CT2	CT2	4 + 3	Max	158	X	23.5	2.26	9.6	93.89	90.35

GSC, Gleason score; ADT, androgen deprivation therapy; CTx, chemotherapy/in all cases Docetaxel; B, bicalutamide 150 mg/d; L, leuprorelin 11.25 mg/3 months; Max, maximal androgen blockade (leuprorelin 11.25 mg/3 months + bicalutamide 50 mg/d)

Changes in PSA and PSMA-derived tumor volumes (primary tumor, lymph node metastases and bone metastases), PSMA-TV and TL-PSMA. Patients with a T2 PSA > 1 ng are in italics

^aPatient 8 underwent TUR-P in the meantime